Home » Stocks » GMDA

Gamida Cell Ltd. (GMDA)

Stock Price: $9.84 USD 0.45 (4.79%)
Updated Jan 19, 2021 4:00 PM EST - Market closed
Market Cap 464.54M
Revenue (ttm) n/a
Net Income (ttm) -34.35M
Shares Out 24.93M
EPS (ttm) -1.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $9.84
Previous Close $9.39
Change ($) 0.45
Change (%) 4.79%
Day's Open 9.92
Day's Range 9.75 - 10.48
Day's Volume 1,397,603
52-Week Range 2.79 - 11.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the full ...

Business Wire - 2 weeks ago

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that company managem...

Business Wire - 4 weeks ago

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that its previ...

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that it has be...

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the pricing of...

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the launch of ...

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the compa...

The Motley Fool - 1 month ago

Early data for this company's natural killer cells is drawing lots of attention.

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today will be providing an upd...

Benzinga - 1 month ago

Gamida Cell (NASDAQ: GMDA) shares are trading higher on Monday following the company's Saturday GDA-201 presentation at the American Society of Hematology Annual Meeting. Gamida CellĀ is a biop...

Other stocks mentioned: HOOK
Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced in an oral pre...

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that it will host a ...

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, C...

Seeking Alpha - 2 months ago

Gamida Cell Ltd (GMDA) CEO Julian Adams on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial res...

Business Wire - 2 months ago

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that updated data from the ongoing Phase 1 clinical study of GDA-2...

Business Wire - 2 months ago

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, P...

Business Wire - 2 months ago

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell announced that it will report its third quarter 2020 financial results and provide a company update on November 10, 2020.

Seeking Alpha - 2 months ago

Gamida Cell recently executed a secondary at $4.50 a share on the back of positive Phase 3 clinical data for its lead asset. The cell therapy biotech now trades at half its 2018 post IPO price...

Business Wire - 3 months ago

BOSTON & MINNEAPOLIS--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell and Be The Match BioTherapiesĀ® today announced an expansion of their strategic collaboration for investigational omidubicel.

Zacks Investment Research - 3 months ago

Gamida Cell (GMDA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Business Wire - 3 months ago

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell will present at the annual Cell & Gene Meeting on the Mesa to be held virtually October 12 - 16, 2020.

Business Wire - 3 months ago

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell announced that its Phase 3 clinical study of omidubicel in bone marrow transplant met all three secondary endpoints.

Business Wire - 4 months ago

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell today announced data from an observational study being presented at the virtual Cord Blood Connect Meeting.

Business Wire - 4 months ago

BOSTON--(BUSINESS WIRE)---- $GMDA--Gamida Cell will participate in three upcoming virtual investor conferences in September.

Business Wire - 4 months ago

BOSTON--(BUSINESS WIRE)---- $GMDA #BMT--Gamida Cell will host a two-part virtual miniseries in September focused on key topics related to its investigational cell therapy omidubicel.

Business Wire - 5 months ago

BOSTON--(BUSINESS WIRE)---- $GMDA--Gamida Cell will webcast its Annual Meeting of Stockholders on Thursday, September 10, 2020, at 10:00 a.m. ET.

Seeking Alpha - 5 months ago

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q2 2020 Results - Earnings Call Transcript

Benzinga - 5 months ago

Shares of Gamida Cell (NASDAQ:GMDA) moved higher by 1.6% in pre-market trading after the company reported Q2 results.

Zacks Investment Research - 5 months ago

Gamida Cell (GMDA) will provide updates on its pipeline candidates when it releases second-quarter 2020 results.

Zacks Investment Research - 5 months ago

Is (GMDA) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 7 months ago

Gamida Cell (GMDA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 7 months ago

Top Ranked Momentum Stocks to Buy for May 28th

Other stocks mentioned: AAWW, AXU, NCNA
Zacks Investment Research - 7 months ago

Gamida Cell (GMDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 7 months ago

Top Ranked Momentum Stocks to Buy for May 22nd

Other stocks mentioned: AAWW, CALM
Seeking Alpha - 7 months ago

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Gamida Cell has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Seeking Alpha - 1 year ago

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q1 2019 Results - Earnings Call Transcript

About GMDA

Gamida Cell, a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a nicotinamide expanded hematopoietic stem cells and differentiated immune cells, including T cells that is in Phase 3 studies in patients with high-risk hematologic malignancies, as well as in Phase 1/2 clinical trial in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 stud... [Read more...]

Industry
Biotechnology
IPO Date
Oct 26, 2018
CEO
Dr. Julian Adams Ph.D.
Employees
79
Stock Exchange
NASDAQ
Ticker Symbol
GMDA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Gamida Cell stock is "Buy." The 12-month stock price forecast is 15.17, which is an increase of 54.17% from the latest price.

Price Target
$15.17
(54.17% upside)
Analyst Consensus: Buy